Med · Dec 8, 2023

SURMOUNTing body weight barriers in type 2 diabetes

By Novikoff A, Müller TD

The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues set out to examine the weight loss efficacy of the GIPR:GLP-1R co-agonist tirzepatide in patients with obesity and type 2 diabetes, reporting that tirzepatide has unprecedented efficacy in a magnitude historically considered almost unattainable.¹.

doi.org/10.1016/j.medj.2023.11.007 Open access PubMed 38070476 Interventions